Phase I/Ib study of concurrent intravenous (IV) and intrathecal (IT) nivolumab (N) and relatlimab (R) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD).

Authors: Isabella Claudia Glitza, Suzanne Phillips, Ida John, Roland L. Bassett, Michelle L. Rohlfs, Jessie Richard, Masood Iqbal, Ian E. McCutcheon, Sherise D. Ferguson, Jeffrey S. Weinberg, Golnaz Morad, Adi Diab, Rodabe Navroze Amaria, Jennifer Leigh McQuade, Alexandra Ikeguchi, Hussein A. Tawbi, Elizabeth M. Burton, Michael A. Davies

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps9592

Source: Full article

---

Abstract

TPS9592